Cabazitaxel, a new taxane with favorable properties

Drugs of Today

Volumn 46, Issue 10, 2010, Pages 735-742

  Bouchet, B P ^a   Galmarini, Carlos M ^b,c  

^a UNIVERSITÉ LYON 1   (France)

^b CNRS   (France)

^c Cell Biology Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE; 4 ACETOXY 13 ((3 ((TERT BUTOXYCARBONYL)AMINO) 2 HYDROXY 3 PHENYLPROPANOYL)OXY) 1 HYDROXY 7,10 DIMETHOXY 9 OXO 5,20 EPOXYTAX 11 EN 2 YL BENZOATE; 4-ACETOXY-13-((3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOYL)OXY)-1-HYDROXY-7,10-DIMETHOXY-9-OXO-5,20-EPOXYTAX-11-EN-2-YL BENZOATE; ANTINEOPLASTIC AGENT; TAXOID;

ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLON CARCINOMA; CROSS RESISTANCE; CYTOTOXICITY; DEEP TENDON REFLEX; DEPOLYMERIZATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FOLLOW UP; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMORRHAGIC CYSTITIS; HUMAN; ISOTOPE LABELING; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; METASTATIC CASTRATION RESISTANT PROTATE CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PARESTHESIA; PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CARCINOMA; RADIOACTIVITY; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ANIMAL; FEMALE; MALE; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NEOPLASMS; TAXOIDS;

EID: 79952198747     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.10.1519019     Document Type: Review

References (35)

1. Downing, K.H., Nogales, E. Tubulin and microtubule structure. Curr Opin Cell Biol 1998, 10(1): 16-22.
2. Nogales, E., Wolf, S.G., Downing, K.H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998, 391(6663): 199-203. (Pubitemid 28092482)
3. Mitchison, T., Kirschner, M. Dynamic instability of microtubule growth. Nature 1984, 312(5991): 237-42. (Pubitemid 15201998)
4. Li, X., Nicklas, R.B. Tension-sensitive kinetochore phosphorylation and the chromosome distribution checkpoint in praying mantid spermatocytes. J Cell Sci 1997, 110(Pt. 5): 537-45. (Pubitemid 27153968)
5. Nicklas, R.B. How cells get the right chromosomes. Science 1997, 275(5300): 632-7.
6. Aapro, M.S., Harper, P., Johnson, S.A., Vermorken, J.B. Developments in cytotoxic chemotherapy: Advances in treatment utilizing vinorelbine. Crit Rev Oncol Hematol 2001, 40(3): 251-63. (Pubitemid 33114369)
7. Jackson, J.R., Patrick, D.R., Dar, M.M., Huang, P.S. Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat Rev Cancer 2007, 7(2): 107-17.
8. Zhou, J., Giannakakou, P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005, 5(1): 65-71.
9. Twelves, C., Loesch, D., Blum, J.L. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28(18): A1004.
10. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2(1): 1-17. (Pubitemid 34649866)
11. Lin, S., Ojima, I. Recent strategies in the development of taxane anticancer drugs. Exp Op Ther Patents 2000, 10(6): 869-89. (Pubitemid 30342636)
12. Lee, J.J., Kelly, W.K. Epothilones: Tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009, 6(2): 85-92.
13. Pronzato, P. New therapeutic options for chemotherapy-resistant metastatic breast cancer: The epothilones. Drugs 2008, 68(2): 139-46.
14. Cigler, T., Vahdat, L. Integrating epothilones into the treatment of patients with metastatic breast cancer: Clinical perspectives on incorporating recent data in the practice setting. Clin Breast Cancer 2008, 8(Suppl. 4): S166-70.
15. Attard, G., Greystoke, A., Kaye, S., De Bono, J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006, 54(2): 72-84.
16. Greenberger, L.M., Lothstein, L., Williams, S.S., Horwitz, S.B. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 1988, 85(11): 3762-6.
17. Hari, M., Wang, Y., Veeraraghavan, S., Cabral, F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2003, 2(7): 597-605.
18. Ranganathan, S., Dexter, D.W., Benetatos, C.A., Chapman, A.E., Tew, K.D., Hudes, G.R. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996, 56(11): 2584-9.
19. Zhang, C.C., Yang, J.M., White, E., Murphy, M., Levine, A., Hait, W.N. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998, 16(12): 1617-24. (Pubitemid 28159910)
20. Dykes, D.J., Sarsat, P.J., Bissery, M.C. Efficacy evaluation of TXD258, a toxoid compound against orthotopic and subcutaneous glioblastomas. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1916.
21. Vrignaud, P., Lejeune, P., Lavelle, F., Chaplin, D., Bissery, M.C. In vivo efficacy of TXD258, a new toxoid against human tumor xenografts. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1365.
22. Bissery, M.C., Bouchard, H., Riou, J.F. Preclinical evaluation of TXD258, a new toxoid. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1364.
23. Mita, A.C., Denis, L.J., Rowinsky, E.K. et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15(2): 723-30.
24. Aller, A.W. In vitro activity of TXD258 in chemotherapeutlc resistant tumor xenografts. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1923.
25. Archimbaud, Y., Gires, P., Pellerin, R. et al. Pharmacokinetics of a new toxoid, 14C-TXD258, in blood, plasma and brain of the mouse, rat and dog. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1375.
26. Archimbaud, Y., Gires, P., Pellerin, R. et al. Mouse plasma and tumor pharmacokinetics of TXD258. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 1373.
27. Cisternino, S., Bourasset, F., Archimbaud, Y., Semiond, D., Sanderink, C., Scherrmann, J.M. Nonlinear accumulation in the brain of the new toxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003, 138(7): 1367-75. (Pubitemid 36543135)
28. Fumoleau, P. Phase I and pharmacokinetic studies of RPR116258A given as a weekly 1-h infusion at day 1, day 8, day 15 and day 22 every 5 weeks in patients with advanced solid tumors. AACR-NCI-EORTC Int Conf Mol Target Cancer Ther 2001, A282.
29. Goetz, A.D., Denis, L.J. et al. Phase I and pharmacokinetic study of RPR116258A, a novel taxane derivative, administered intravenously over 1 hour every 3 weeks. Proc Am Soc Clin Oncol (ASCO) 2001, 20 (Pt.1): Abst 419.
30. Pivot, X., Koralewski, P., Hidalgo, J.L. et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008, 19(9): 1547-52.
31. Sartor, A.O., Oudard, S., Ozguroglu, M. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Genitourin Cancers Symp (March 5-7, San Francisco) 2010, Abst 9.
32. Effect of cabazitaxel on the QTc interval in cancer patients (QT-Cab) (NCT01087021). ClinicalTrials.gov Web site, September 6, 2010.
33. Safety and pharmacokinetic study of cabazitaxel in patients with advanced solid tumors and liver impairment (NCT01140607). ClinicalTrials.gov Web site, September 6, 2010.
34. Dose-escalation, safety, pharmacokinetics study of cabazitaxel with gemcitabine in patients with solid tumor (NCT01001221). ClinicalTrials.gov Web site, September 6, 2010.
35. De Bono, J.S., Oudard, S., Ozguroglu, M. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010, 28(Suppl. 15): Abst 4508.